Global Lupus Experts Publish First Paper to Define Disease Modification in Lupus

Angela Carroll, US Medical Affairs Scientific Director-Immuno-inflammation at ​GlaxoSmithKline (​GSK​)​, a global health care company, discusses the first published article to put forth a definition of disease modification in systemic lupus erythematosus (SLE), including lupus nephritis (LN). Co-authored by some of the world’s top lupus experts, the paper appears in the latest issue of “Lupus Science & Medicine” (Mar 2022) and marks an important step toward identifying treat-to-target therapies for the 5 million people worldwide suffering from SLE and LN. 

Angela Carroll is the US Medical Affairs Scientific Director-Immuno-inflammation at GSK. Over her 16+ years with the company, she has become a principal contributor in US Medical Affairs across multiple rheumatology compounds. She has an extensive background in medical affairs within the systemic lupus erythematosus and lupus nephritis space. Additionally, she partners with the Global medical, R&D, and commercial strategy teams to develop and execute the business’s medical affairs strategy plan. She received her master’s degree in Life Sciences at North Carolina State University. She is the co-author on the recent paper published in Lupus Science & Medicine (found here: https://lupus.bmj.com/content/9/1/e000634)

Liked it? Take a second to support healthprofessionalradio on Patreon!

0 Comments

Leave a Reply

You must be logged in to post a comment.